Posted On: 11/24/2013 9:25:49 PM
Post# of 2022
MIT and NMU join to fight antimicrobial resistance,
specifically MRSA !!!
Northern Michigan University and Micro Imaging Technology to Collaborate on Rapid
Detection of Staph and MRSA Pathogens
SAN CLEMENTE, CA--(Marketwired - Oct 25, 2013) - Micro Imaging Technology, Inc.
(OTCQB: MMTC) announced today that it will collaborate with the Northern Michigan
University (NMU) Department of Biology to expand MIT's technology to identify and
differentiate Staphylococcus aureus (S. aureus) and Methicillin Resistant
Staphylococcus aureus (MRSA). The goal of the strategic research with NMU is to
rapidly and cost-effectively identify these two particular healthcare threats
using the MIT 1000 System, a bacterial cell based identification system that can
identify pathogenic bacteria in three minutes (average) at significant cost
savings per test.
At this stage the collaboration involves scientists from MIT and NMU gathering
preliminary data and developing collaborative research proposals seeking funding
in support of continued research.
Dr. Josh S. Sharp, Ph.D., assistant professor at the Northern Michigan University
Department of Biology, will direct the NMU portion of the research at his
laboratory in Marquette, MI. Sharp received a B.S. at Western Michigan University
in 1998 and his Ph.D. in Biological Sciences at the Mount Sinai School of Medicine
of New York University in 2006. His initial research in this collaboration will
focus on clinical applications of the MIT 1000.
"Being able to quickly identify if a patient has an S. aureus infection, and
whether or not that S. aureus is MRSA, a strain of S. aureus resistant to certain
antibiotics would be extremely useful in dictating the proper course of treatment
for that patient, and ultimately increase the likelihood of a successful patient
outcome," Sharp said.
Micro Imaging Technology's Chief Scientist, Dr. David Haavig, is the program
director of the effort and will lead MIT's team in the collaboration. He received
his Ph.D. in Physics from Purdue University in 1983. Haavig was instrumental in
developing the MIT 1000, a stand-alone, rapid laser based bacteria detection and
identification technology that can detect pathogenic bacteria and complete an
identifying test in less than three minutes (average) at significant cost savings
per test.
"We are extremely pleased to be working with Dr. Sharp and his staff on this
project," Haavig said. "We are confident that this collaborative effort will be
highly successful and the result of our teamwork and the clinical implications for
this technology may very well prove to be immeasurable."
http://www.marketwired.com/press-release/nort...ity-micro-
imaging-technology-collaborate-on-rapid-detection-otcqb-mmtc-1844919.htm
http://www.nmu.edu/campus/node/149
http://news.rapidmicromethods.com/2013/10/nor...rsity-and-
micro.html
http://investing.businessweek.com/research/st...apshot.asp ?
privcapId=4293072
https://research.tdwaterhouse.ca/research/pub...0-298u7834
-1
http://www.firmenpresse.de/pressrelease309398.html
http://blog.qualitystocks.net/stocks-to-watch...logy-mmtc-
partners-with-northern-michigan-university-to-advance-mit-1000-capabilities/
http://technology.rsspump.com/?key=2013102512...niversity-
micro
http://www.industriesnews.net/story?sid=s2179...mp;cid=401
http://ofinancialinc.com/ofc-stock-market-new...rsity-and-
micro-imaging-technology-to-collaborate-on-rapid-detection-of-staph-and-mrsa-
pathogens
http://www.businesspress24.com/print-pressrel...76140.html
http://www.beyond.com/news/comments/92021129
http://news.feedfury.com/content/65652819-mic...-partners-
with-northern-michigan-university-to-advance-mit-1000-capabilities.html
http://www.medical-answers.org/hd/index.php?t...University
http://up.secondwavemedia.com/innovationnews/...11313.aspx
http://www.serioustraders.com/clients.php?clientid=mmtc#head
http://www.vietba.com.vn/index.php/en/bacteri...ation.html
http://blog.qualitystocks.net/category/micro-...s-inc-mmtc
-ob/
http://www.qualitystocks.net/messageboard/vie...mp;t=20576
http://www.wef.org/About/StoryPage_nbp.aspx?s...=191504518
http://www.highbeam.com/doc/1G1-238053338.html
https://wellsfargoadvisors.mworld.com/m/m.w?l...=637649131
http://www.asmcue.org/documents/2012_ASMCUE_F...AM_V.1.pdf
Recent data suggest that at least 2 million Americans fall ill from antimicrobial
-resistant pathogens every year, 23 000 of whom die from these infections.1
Antimicrobial resistance also continues to increase in Europe, especially in Gram
-negative bacterial pathogens;2 the excess mortality attributable to resistant
hospital infections exceeds 25 000 deaths annually, and associated health-care
costs and productivity losses total at least €1·5 billion each year.3 In addition
to the direct effects on mortality and morbidity and the economic burden, a loss
of effective antibiotics places at risk many of the procedures of modern medicine
such as cancer chemotherapy, organ transplantation, and the care of premature
babies.
Many of the national academies of science and medicine have a long history of
interest in antimicrobial resistance, both in analysing the issues and proposing
solutions.
Global recommendations from the InterAcademy Panel and InterAcademy Medical Panel
call for action to tackle antimicrobial resistance~
Develop, improve, and promote integrated surveillance systems for antimicrobial
resistance in human and animal health sectors.......
Encourage industry innovation and public—private collaborative research and
development programmes for therapeutics, diagnostics, and vaccines.
Increase research capacity, including clinical research capacity, worldwide.....
http://www.thelancet.com/journals/langlo/arti...X/fulltext
specifically MRSA !!!
Northern Michigan University and Micro Imaging Technology to Collaborate on Rapid
Detection of Staph and MRSA Pathogens
SAN CLEMENTE, CA--(Marketwired - Oct 25, 2013) - Micro Imaging Technology, Inc.
(OTCQB: MMTC) announced today that it will collaborate with the Northern Michigan
University (NMU) Department of Biology to expand MIT's technology to identify and
differentiate Staphylococcus aureus (S. aureus) and Methicillin Resistant
Staphylococcus aureus (MRSA). The goal of the strategic research with NMU is to
rapidly and cost-effectively identify these two particular healthcare threats
using the MIT 1000 System, a bacterial cell based identification system that can
identify pathogenic bacteria in three minutes (average) at significant cost
savings per test.
At this stage the collaboration involves scientists from MIT and NMU gathering
preliminary data and developing collaborative research proposals seeking funding
in support of continued research.
Dr. Josh S. Sharp, Ph.D., assistant professor at the Northern Michigan University
Department of Biology, will direct the NMU portion of the research at his
laboratory in Marquette, MI. Sharp received a B.S. at Western Michigan University
in 1998 and his Ph.D. in Biological Sciences at the Mount Sinai School of Medicine
of New York University in 2006. His initial research in this collaboration will
focus on clinical applications of the MIT 1000.
"Being able to quickly identify if a patient has an S. aureus infection, and
whether or not that S. aureus is MRSA, a strain of S. aureus resistant to certain
antibiotics would be extremely useful in dictating the proper course of treatment
for that patient, and ultimately increase the likelihood of a successful patient
outcome," Sharp said.
Micro Imaging Technology's Chief Scientist, Dr. David Haavig, is the program
director of the effort and will lead MIT's team in the collaboration. He received
his Ph.D. in Physics from Purdue University in 1983. Haavig was instrumental in
developing the MIT 1000, a stand-alone, rapid laser based bacteria detection and
identification technology that can detect pathogenic bacteria and complete an
identifying test in less than three minutes (average) at significant cost savings
per test.
"We are extremely pleased to be working with Dr. Sharp and his staff on this
project," Haavig said. "We are confident that this collaborative effort will be
highly successful and the result of our teamwork and the clinical implications for
this technology may very well prove to be immeasurable."
http://www.marketwired.com/press-release/nort...ity-micro-
imaging-technology-collaborate-on-rapid-detection-otcqb-mmtc-1844919.htm
http://www.nmu.edu/campus/node/149
http://news.rapidmicromethods.com/2013/10/nor...rsity-and-
micro.html
http://investing.businessweek.com/research/st...apshot.asp ?
privcapId=4293072
https://research.tdwaterhouse.ca/research/pub...0-298u7834
-1
http://www.firmenpresse.de/pressrelease309398.html
http://blog.qualitystocks.net/stocks-to-watch...logy-mmtc-
partners-with-northern-michigan-university-to-advance-mit-1000-capabilities/
http://technology.rsspump.com/?key=2013102512...niversity-
micro
http://www.industriesnews.net/story?sid=s2179...mp;cid=401
http://ofinancialinc.com/ofc-stock-market-new...rsity-and-
micro-imaging-technology-to-collaborate-on-rapid-detection-of-staph-and-mrsa-
pathogens
http://www.businesspress24.com/print-pressrel...76140.html
http://www.beyond.com/news/comments/92021129
http://news.feedfury.com/content/65652819-mic...-partners-
with-northern-michigan-university-to-advance-mit-1000-capabilities.html
http://www.medical-answers.org/hd/index.php?t...University
http://up.secondwavemedia.com/innovationnews/...11313.aspx
http://www.serioustraders.com/clients.php?clientid=mmtc#head
http://www.vietba.com.vn/index.php/en/bacteri...ation.html
http://blog.qualitystocks.net/category/micro-...s-inc-mmtc
-ob/
http://www.qualitystocks.net/messageboard/vie...mp;t=20576
http://www.wef.org/About/StoryPage_nbp.aspx?s...=191504518
http://www.highbeam.com/doc/1G1-238053338.html
https://wellsfargoadvisors.mworld.com/m/m.w?l...=637649131
http://www.asmcue.org/documents/2012_ASMCUE_F...AM_V.1.pdf
Recent data suggest that at least 2 million Americans fall ill from antimicrobial
-resistant pathogens every year, 23 000 of whom die from these infections.1
Antimicrobial resistance also continues to increase in Europe, especially in Gram
-negative bacterial pathogens;2 the excess mortality attributable to resistant
hospital infections exceeds 25 000 deaths annually, and associated health-care
costs and productivity losses total at least €1·5 billion each year.3 In addition
to the direct effects on mortality and morbidity and the economic burden, a loss
of effective antibiotics places at risk many of the procedures of modern medicine
such as cancer chemotherapy, organ transplantation, and the care of premature
babies.
Many of the national academies of science and medicine have a long history of
interest in antimicrobial resistance, both in analysing the issues and proposing
solutions.
Global recommendations from the InterAcademy Panel and InterAcademy Medical Panel
call for action to tackle antimicrobial resistance~
Develop, improve, and promote integrated surveillance systems for antimicrobial
resistance in human and animal health sectors.......
Encourage industry innovation and public—private collaborative research and
development programmes for therapeutics, diagnostics, and vaccines.
Increase research capacity, including clinical research capacity, worldwide.....
http://www.thelancet.com/journals/langlo/arti...X/fulltext
(0)
(0)
